By Elisha Fieldstadt
The company thinks it could make millions of treatment courses of remdesivir available by the end of the year if it receives FDA approval, the Gilead CEO said.
The maker of Remdesivir, an experimental drug for treatment of the coronavirus, is moving very quickly with the FDA for authorization to get the drug to patients, the CEO of the company, Gilead Sciences, said Friday.
Gilead is also working to expand its capacity for producing remdesivir, CEO Daniel O’Day told the “TODAY” show in an exclusive interview.
The company thinks it could make millions of treatment courses available by the end of the year, O’Day said. Its production capacity has already gone from 5,000 treatment courses to 100,000, he said.
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters